Kari Laine
Department of Pharmacology and Clinical Pharmacology
University of Turku
Finland
Name/email consistency: high
- Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics. Laine, K., De Bruyn, S., Björklund, H., Rouru, J., Hänninen, J., Scheinin, H., Anttila, M. Eur. J. Clin. Pharmacol. (2004)
- Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy. Laine, K., Kytölä, J., Bertilsson, L. Ther. Drug. Monit (2004)
- Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Laine, K., Heikkinen, T., Ekblad, U., Kero, P. Arch. Gen. Psychiatry (2003)
- A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Laine, K., Yasar, U., Widén, J., Tybring, G. Pharmacol. Toxicol. (2003)
- Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Laine, K., Ahokoski, O., Huupponen, R., Hänninen, J., Palovaara, S., Ruuskanen, J., Björklund, H., Anttila, M., Rouru, J. Eur. J. Clin. Pharmacol. (2003)
- CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. Laine, K., Anttila, M., Nyman, L., Wahlberg, A., Bertilsson, L. Eur. J. Clin. Pharmacol. (2001)
- Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Laine, K., Tybring, G., Härtter, S., Andersson, K., Svensson, J.O., Widén, J., Bertilsson, L. Clin. Pharmacol. Ther. (2001)
- No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Laine, K., Tybring, G., Bertilsson, L. Clin. Pharmacol. Ther. (2000)
- Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Laine, K., Palovaara, S., Tapanainen, P., Manninen, P. Clin. Pharmacol. Ther. (1999)